RxDoctor Payments Data

Miguel Giannoni Delgado, MD

Interventional Cardiology · St Petersburg, FLNPI 1619124237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $627 and has fallen 67.6% since, to $203 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.

$2,618in general payments, 2019–2025

Across 74 payments — averaging $35.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$543
  • Abiomed$433
  • AstraZeneca$382
  • Medtronic$216
  • Cardiovascular Systems Inc.$138
  • Amgen$132
  • plus $775 from 13 others

What the payments were for

  • Food & beverage$2,606100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,618 in reported general payments places this provider in the 20th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida →

Medicare billing

Part B allowed, 2024
$276,500
Medicare patients
1,329
Services billed
2,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$170,699
XareltoRivaroxaban56$47,321
EntrestoSacubitril/Valsartan16$23,281
Metoprolol Succinate230$2,583
ClopidogrelClopidogrel Bisulfate158$1,698
Atorvastatin Calcium162$1,401
Isosorbide Mononitrate ErIsosorbide Mononitrate97$1,213
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$1,203
Carvedilol166$1,187
Losartan Potassium69$823
Nitroglycerin43$665
Amlodipine Besylate154$570
Rosuvastatin Calcium37$486
Metoprolol Tartrate69$344
Lisinopril91$332

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in St Petersburg

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →